hUGT1A1
Nomenclature
C57BL/6JSmo-Ugt1a1tm1(hUGT1A1)Smoc
Cat. NO.
NM-HU-232902
Strain State
Embryo Cryopreservation
Gene Summary
Gene Symbol
Ugt1a1
Model Description
Validation Data

Fig.1 Detection of UGT1A1 expression in liver by RT-PCR. Mouse Ugt1a1 mRNA (286 bp) was detectable both in wild-type C57BL/6 mice and heterozygous hUGT1A1 knockin mice. Human UGT1A1 mRNA (426 bp) was detectable only in heterozygous hUGT1A1 knockin mice but not in WT mice. Liver RNA was extracted from 12-week-old male WT C57BL/6 (n=2) and 11-week-old male heterozygous hUGT1A1 knockin mice (n=2), then cDNA libraries were synthesized by reverse transcription, followed by PCR with mRNA primers.
Abbr. M, marker; HE, heterozygous; WT, wild type.

Fig.2 Detection of UGT1A1 expression in hUGT1A1 mice by WB. Human UGT1A1 was exclusively detectable in liver, small intestine and colon tissues from heterozygous hUGT1A1 mice with a human UGT1A1 specific antibody but not in WT mice. The liver, small intestine and colon tissue lysates were collected from 12-week-old male WT C57BL/6 mice and 11-week-old male heterozygous hUGT1A1 mice, and then analyzed by western blot.
Abbr. HE, heterozygous; WT, wild type.

Fig.3 Blood Biochemical test of WT mice and hUGT1A1 mice. hUGT1A1 mice exhibited higher DBIL levels but similar TBIL, ALT, and AST levels compared to WT mice, indicating normal human UGT1A1 activity in catalyzing the glucuronidation of unconjugated bilirubin (UCB) to DBIL. Serum was collected from 4.5-month-old female wild-type C57BL/6 mice (n=5) and 4.5-month-old female heterozygous hUGT1A1 mice (n=4) to measure levels of (A) direct bilirubin (DBIL), (B) total brilirubin (TBIL), (C) alanine aminotransferase (ALT), and (D) aspartate aminotransferase (AST) (Mean±SEM, T-test, *p<0.05; ns, no significance).
Abbr. HE, heterozygous; WT, wild type.
You may also like
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreWorkshop:Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more